| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
867,229 |
| 52
Week Range: |
$187.64 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
19,405 |
57,754 |
513,978 |
| Total Sell Value |
$0 |
$4,136,219 |
$11,851,618 |
$91,955,621 |
| Total People Sold |
0 |
2 |
7 |
9 |
| Total Sell Transactions |
0 |
2 |
21 |
74 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Liu Jean I |
GC/EVP, Legal Affairs |
• – – |
2021-09-23 |
4 |
A |
$166.22 |
$26,595 |
D/D |
160 |
69,091 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2021-09-23 |
4 |
A |
$166.22 |
$18,617 |
D/D |
112 |
51,296 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2021-09-23 |
4 |
A |
$166.22 |
$33,410 |
D/D |
201 |
126,647 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2021-09-23 |
4 |
A |
$166.22 |
$595,400 |
D/D |
3,582 |
88,921 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-09-23 |
4 |
A |
$166.22 |
$33,410 |
D/D |
201 |
57,689 |
|
- |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-09-23 |
4 |
A |
$166.22 |
$118,681 |
D/D |
714 |
669,172 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-09-08 |
4 |
AS |
$150.00 |
$900,000 |
D/D |
(6,000) |
57,488 |
|
-13% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-09-08 |
4 |
OE |
$26.10 |
$156,600 |
D/D |
6,000 |
63,488 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2021-08-31 |
4 |
AS |
$167.52 |
$189,795 |
D/D |
(1,133) |
51,184 |
|
-14% |
|
| Liu Jean I |
GC/EVP, Legal Affairs |
• – – |
2021-08-31 |
4 |
AS |
$167.52 |
$611,097 |
D/D |
(3,648) |
68,931 |
|
-14% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2021-08-31 |
4 |
AS |
$167.52 |
$772,414 |
D/D |
(4,611) |
85,339 |
|
-14% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2021-08-31 |
4 |
AS |
$167.52 |
$667,884 |
D/D |
(3,987) |
126,446 |
|
-14% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2021-08-31 |
4 |
AS |
$167.52 |
$600,376 |
D/D |
(3,584) |
57,488 |
|
-14% |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-08-31 |
4 |
AS |
$167.52 |
$2,404,015 |
D/D |
(14,351) |
668,458 |
|
-14% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-08-31 |
4 |
S |
$168.19 |
$1,772,575 |
D/D |
(10,432) |
682,809 |
|
14% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-08-30 |
4 |
S |
$166.79 |
$5,957,816 |
D/D |
(35,706) |
693,241 |
|
14% |
|
| Siegall Clay B |
President and CEO |
• • – |
2021-08-27 |
4 |
S |
$168.86 |
$2,416,390 |
D/D |
(14,294) |
728,947 |
|
14% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2021-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
11,095 |
130,433 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2021-08-16 |
4 |
AS |
$154.55 |
$82,377 |
D/D |
(533) |
119,338 |
|
1% |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2021-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
9,246 |
72,579 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2021-08-16 |
4 |
AS |
$154.55 |
$110,970 |
D/D |
(718) |
63,333 |
|
1% |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2021-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
9,907 |
52,317 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2021-08-16 |
4 |
AS |
$154.55 |
$120,088 |
D/D |
(777) |
42,410 |
|
1% |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
30,821 |
743,241 |
|
- |
|
| Siegall Clay B |
President & CEO |
• • – |
2021-08-16 |
4 |
AS |
$154.55 |
$431,051 |
D/D |
(2,789) |
712,420 |
|
1% |
|
1805 Records found
|
|
Page 10 of 73 |
|
|
